Myeloma Genomics and Microenvironment and immune profiling

P-197: Testing and Reporting of FISH Studies in Multiple Myeloma: Recommendations from the Cancer Genomics Consortium Myeloma Working Group for Best Practices

P-198: Immunomodulatory Effects of Daratumumab on the Bone Marrow Microenvironment in Multiple Myeloma: Insights from Single-Cell Analyses

P-199: Artificial Intelligence system to predict t(11,14) status in multiple myeloma patients by leveraging the correlation of plasma cell morphology and genetics

P-200: Semi-automated Interphase FISH (iFISH) Spot Scoring in CD138-Positive Cells: Validation Study for Genetic Abnormalities Detection in Multiple Myeloma

P-201: Phosphatidylcholine Deactivates Cytotoxic CD8+ T Cells Through UFMylation Mediated by Exosomal SerpinB9 in Multiple Myeloma

P-203: Ability to perform spatial transcriptomics in FFPE decalcified bone marrow samples of patients with precursor myeloma

P-204: Deciphering the interplay of immune alterations and microbiome changes along multiple myeloma evolution from premalignant conditions

P-205: Identification of therapy induced evolution in MRD clones and resistance pathways in multiple myeloma through single-cell sequencing

P-206: Type I interferon response in monocytes altered monocyte differentiation pathways and promotes multiple myeloma proliferation

P-207: Identification of uniquely expressed proteins in bone marrow mesenchymal stromal cells of multiple myeloma patients with poor therapeutic response.

P-208: Clonal evolution of multiple myeloma following the mutagenic impact of radiotherapy

P-209: The Influence of the Gut Microbiome on Myeloma Progression

P-210: Evaluation of IL-6, IL-1β and TNF-α polymorphisms in Multiple Myeloma patients

P-211: Clinical characteristics and prognostic values of 1p32.3 deletion in newly diagnosed multiple myeloma patients

P-212: Single nucleotide variants in PTPRD, NOTCH4, SH3RF3, DCC, and CSMD genes as potential prognostic biomarkers of newly-diagnosed multiple myeloma.

P-213: Comparative Genomic Analysis of Active Multiple Myeloma and Monoclonal Gammopathy of Uncertain Significance Using Single Nucleotide Variants Microarray

P-214: Examining the role of XRCC1 and BRCA1 gene variants on survival and treatment response in patients with multiple myeloma from South America and Spain

P-215: Cancer Dynamics of Multiple Myeloma

P-216: IRF2 Inhibition Impairs Cell Migration and Triggers Necroptosis in Multiple Myeloma

P-217: The interaction between myeloma cells and microenvironment via LILRB4 signaling promote myeloma progression

P-218: Inadequacy of MYC gene expression alone as a risk determinant in Multiple Myeloma – the importance of associated MIZ1 expression

P-219: Longitudinal analysis of t(11;14) and t(4;14) genomes reveals distinct evolutionary trajectories in multiple myeloma.

P-220: Profiling of immune checkpoints in the myeloma microenvironment

P-221: Plasma cell lineage and driver heterogeneity associated with multiple myeloma progression

P-222: Analysis of Normal Plasma Cell Distribution Across Distinct Age Cohorts Reveals Age Dependent Changes

P-223: Clinicopathologic Features of 73 Patients with TP53 Mutated Multiple Myeloma

P-224: Autologous transplantation is the strongest prognostic factor for overall survival in Multiple Myeloma patients with deletion 17p: 20-year Real-World experience of the Greek Myeloma Study Group.

P-225: Risk Factors and Prognosis of Extramedullary Disease in Newly-Diagnosed Multiple Myeloma Patients

P-226: Study of T cell receptor (TCR) dynamics in smouldering myeloma (SMM) using TCR sequence clustering to infer contribution of the immune microenvironment to progression to multiple myeloma (MM)

P-227: The significance of complex Karyotype in Multiple Myeloma

P-228: The detection of PR minor clones at Single Cell Level identifies High Risk disease in Multiple Myeloma

P-229: Osteoblastic cells maintain bone forming capacity in fractured vertebrae of patients with myeloma bone disease: evidence from in vivo and in vitro studies

P-231: Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African Ancestry compared with those of non-African Ancestry

P-232: Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)

P-233: Comparative analysis of CXCL12-abundant Reticular (CAR) Cell subpopulations in the Bone Marrow of Healthy Individuals versus MGUS and Multiple Myeloma Patients

P-234: Autocrine IL6 signaling in stromal cells in multiple myeloma influences the bone marrow microenvironment

P-235: Isatuximab as Post-ASCT Therapy in MRD-positive Patients Augments CD8 Effector T Cell Differentiation: Insights from the UKMRA Phase 3 RADAR Study

P-236: Integrated coding and non-coding transcriptomic atlas reveals how malignant plasma cells shape the bone marrow microenvironment in multiple myeloma

P-237: Mapping Racial Disparities in Immune Cell Dysregulations and Multiple Myeloma Outcomes Using Single-Cell Profiling

P-238: Prognostic impact of cytogenetic abnormalities and R2-ISS in multiple myeloma: experience in a Brazilian private hospital

P-239: The burden of circulating tumor plasma cells is associated with the quantity of mesenchymal stromal cells and CXCR4-expressing plasma cells in bone marrow of newly diagnosed multiple myeloma.

P-240: Survival Analysis and Transcriptomic Profiling Unveil Key Genes in Multiple Myeloma: Insights from MMRF CoMMpass Data

P-241: Progression from smouldering myeloma to myeloma is accompanied by an increase in CD56bright bone marrow resident NK cells with reduced NK cell cytotoxic capacity

P-242: Clonal Hematopoiesis of Indeterminate Potential (CHIP) is associated with shorter overall survival (OS) in patients with multiple myeloma

P-243: Cytogenetics abnormalities in patients with newly diagnosed multiple myeloma analyzed by fluorescent in situ hybridization in Chilean patients.

P-244: EFFECTS OF DARATUMUMAB(DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS

P-245: Taking a peek into the cytogenetic profile of an Indian cohort.

P-247: Increased WEE1 expression is predictive of short progression-free survival, independent of standard prognostic factors in multiple myeloma

P-248: CRISPR-based functional genomics studies identify mechanisms of multiple myeloma (MM) cell response to vs. resistance against novel pharmacological mutant-specific KRAS inhibitors.

P-249: Spatial transcriptomics unveils novel disease mechanisms associated with the microenvironment in Multiple Myeloma

P-250: ALTERATION OF THE m6A REGULATORY GENES, WITH THE SPECIAL IMPLICATION OF VIRMA, IS CRUCIAL FOR MULTIPLE MYELOMA DEVELOPMENT

P-251: Bone Marrow Immune Ecosystem Shapes Acquired Daratumumab Resistance in Plasma Cell Myeloma

P-252: Critical roles of LILRB4 in promoting STAT3/PIM1 mediated metabolism in multiple myeloma

P-253: Proteogenomic analysis of hyperdiploid multiple myeloma

P-255: The Specific Transcriptional Profile and Clonal Selection of MGUS-like Behavior Predict an Exceptionally Favorable Prognosis in Multiple Myeloma

P-257: Causal roles of monocyte in mediating effects of gut microbiota in multiple myeloma suggested by a genetic study

P-258: LGR4 promotes plasma cell malignancy and myeloma cell homing by activating NF-κB signaling pathway

P-424: Unveiling the Spectrum of FISH Abnormalities in a Decade-Long Retrospective Study of Multiple Myeloma Patients: Insights from an Underrepresented Population.

P-427: REAL-WORLD PREVALENCE AND MULTI-OMIC ANALYSIS OF T(11;14)-POSITIVE MULTIPLE MYELOMA: FINAL ANALYSIS FROM THE MEDICI STUDY